A COMPARISON OF ORAL ONDANSETRON SYRUP OR INTRAVENOUS ONDANSETRON LOADING DOSE REGIMENS GIVEN IN COMBINATION WITH DEXAMETHASONE FOR THE PREVENTION OF NAUSEA AND EMESIS IN PEDIATRIC AND ADOLESCENT PATIENTS RECEIVING MODERATELY/HIGHLY EMETOGENIC CHEMOTHERAPY

References

• Dupuis L, Chan HSL, Lacey C, McBride J. The management of chemotherapy-induced nausea and vomiting in children. Can J Hosp Pharm. 1986;39:38–44.
   Google Scholar
• Frick SB, Guzzi DelPo E, Keith JA, Davis MS. Chemotherapy-associated nausea and vomiting in pediatric oncology patients. Cancer Nursing. 1998;11:118–124.
   Google Scholar
• Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65:307–314.
   PubMed Web of Science ®Google Scholar
• Bernstein IL. Learned taste aversions in children receiving chemotherapy. Science 1978;200:1302–1303.
   PubMed Web of Science ®Google Scholar
• Dolgin MJ, Katz ER, McGinty K, Siegel SE. Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics. 1985;75:547–552.
   PubMed Web of Science ®Google Scholar
• Allen JC, Gralla R, Reilly L, Kellick M, Young C. Metoclopramide dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Gun Oncol 1985;3:1136–1140.
   Google Scholar
• Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. J Pediatr. 1984;104:138–140.
   Google Scholar
• Graham-Pole J, Wear e J, Engel S, Gardner R, Mehta P, Gross S. Anti-emetics in children receiving cancer chemotherapy: a double-blind prospective randomized study comparing metoclopramide with chlorpromazine. J Clin OncoL 1986;4:1110–1113.
   Google Scholar
• Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemo-therapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 1987;79:946–952.
   Google Scholar
• Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N EnglJ Med. 1979;300:1295–1297.
   PubMed Web of Science ®Google Scholar
• Carden PA, Mitchell SL, Waters KID, Tidemann K, Ekert H. Prevention of cyclophosphamide/cytara-bine-induced emesis with ondansetron in children with leukaemia. J Gun Oncol 1990;8:1531–1535.
   Google Scholar
• Pinkerton CR, Willaims D, Wooton C, Meller ST, McElwain TJ. 5HT3 antagonist ondansetron: an effective outpatient anti-emetic in cancer treatment. Arch Dis Child. 1990;65: 822–825.
   Google Scholar
• Stevens RF. The role of ondansetron in pediatric patients: a review of three studies. Eur J Cancer. 1991;27(Suppl 1):520–522.
   Google Scholar
• Jurgens H, McQuade B. Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children. Oncology. 1992;49:279–285.
   PubMed Web of Science ®Google Scholar
• Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BNIJ. 1991;303:1423–1426.
   Google Scholar
• Roila F, To nato M, CognettiF, et al. Prevention of cisplatin-induced emesis: a double-blind multicentre randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9:675–678.
   PubMed Web of Science ®Google Scholar
• Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron plus dexa-methasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991;338:487–490.
   PubMed Web of Science ®Google Scholar
• The Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. LanceL 1992;340:96–99.
   Google Scholar
• Jantunen IT, Kataja VV, Johansson RT. Ondansetron and tropisetron with dexamethasone in the pro-phylaxis of acute vomiting induced by no n-cisplatin-co ntaining chemotherapy. Ada Oncol 1992;5:573–575.
   Google Scholar
• Alvarez 0, Freeman A, Bedros A, et al. Randomized double-blind crossover ondansetron-dexametha-sone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vom-iting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995;17:145–150.
   Google Scholar
• Cohen IJ, Zehavi N, Buchwald I. Oral ondansetron: an effective ambulatory complement to intra-venous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol OncoL 1995;12:67–72.
   Google Scholar
• Laszlo" Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983; 25:1–7.
   PubMed Web of Science ®Google Scholar
• Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life: consequences of chemotherapy induced emesis. Qual Life Res. 1992;1:331–340.
   PubMedGoogle Scholar
• Soukup M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992;49:295–304.
   Google Scholar